CONMED Corp

Listed Company

CNMDCIK 0000816956NYSELarge AcceleratedElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.37B

Net Income

$47.05M

Total Assets

$2.33B

Equity

$1.03B

Shares Out

30.11M

Op. Cash Flow

$170.69M

CNMD$43.21−12.25% · past yearDBEQ Basic

Daily closing prices

Business

CONMED Corporation is a medical technology company that designs, manufactures and globally distributes surgical devices and equipment for orthopedic and general surgery procedures. The company offers orthopedic products including soft tissue fixation systems, powered instruments, and arthroplasty systems; and general surgery products including insufflation systems, smoke evacuation devices, electrosurgical instruments and endoscopic equipment. CONMED operates through two primary product lines—orthopedic surgery and general surgery—and sells directly to hospitals, surgery centers and healthcare institutions as well as through distributors in over 100 countries, with a significant portion of net sales from international markets.

Summary from 10-K filed 2026-02-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	1,375	1,307	1,245	1,045	1,011
Cost of sales	624	574	568	474	443
Gross profit	750	733	676	571	568
Selling and administrative expense	592	478	503	454	415
Research and development expense	56	54	53	47	44
Operating expenses	648	533	556	501	458
Income from operations	103	200	121	70	110
Interest expense	31	37	40	29	35
Other expense	418,000	0	0	112	1
Income before income taxes	71	163	81	−71	73
Provision for income taxes	24	31	16	10	11
Net income	47	132	64	−81	63
Basic (in dollars per share)	1.52	4.29	2.1	−2.68	2.14
Diluted (in dollars per share)	1.51	4.25	2.04	−2.68	1.94
Cash flow hedging	−7	6	−3	−2	13
Pension liability	3	2	7	8	9
Foreign currency translation adjustments	15	−15	5	−8	−7
Other comprehensive income (loss), before income tax	12	−7	9	−2	15
Provision (benefit) for income taxes related to items in other comprehensive income (loss)	−834,000	2	832,000	2	5
Other comprehensive income (loss), net of income tax	13	−9	8	−4	9
Comprehensive income	60	124	72	−84	72

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	41	24	24	29	21
Accounts receivable, less allowance for doubtful accounts of $6,300 in 2025 and $5,739 in 2024	248	238	242	191	184
Inventories	356	347	318	332	232
Prepaid expenses and other current assets	29	31	31	29	24
Total current assets	673	640	616	581	460
Property, plant and equipment, net	113	116	121	116	109
Deferred income taxes	13	11	11	10	10
Goodwill	807	805	807	815	618
Other intangible assets, net	582	618	649	682	471
Other assets	137	116	96	94	99
Total assets	2,326	2,306	2,300	2,298	1,766
Current portion of long-term debt	712,000	715,000	708,000	70	12
Accounts payable	94	102	88	73	58
Accrued compensation and benefits	82	65	70	55	60
Other current liabilities	139	110	152	99	66
Total current liabilities	315	278	311	297	197
Long-term debt	834	905	973	985	672
Deferred income taxes	80	74	61	67	69
Other long-term liabilities	64	86	121	204	43
Total liabilities	1,293	1,344	1,466	1,552	981
Commitments and contingencies (Note 13)	—	—	—	—	—
Preferred stock, par value $.01 per share; authorized 500,000 shares, none issued or outstanding	0	0	0	0	0
Common stock, par value $.01 per share; 100,000,000 authorized; 31,299,194 issued in 2025 and 2024, respectively	313,000	313,000	313,000	313,000	313,000
Paid-in capital	503	477	447	413	397
Retained earnings	589	560	453	413	497
Accumulated other comprehensive loss	−46	−59	−50	−58	−54
Less: Treasury stock, at cost; 328,097 and 397,860 shares in 2025 and 2024, respectively	−13	−16	−15	−23	−54
Total shareholders' equity	1,033	963	834	746	785
Total liabilities and shareholders' equity	2,326	2,306	2,300	2,298	1,766

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	17	17	16	16	16
Amortization of deferred debt issuance costs	6	6	6	5	4
Amortization	57	55	56	53	54
Stock-based compensation	28	26	24	22	16
Deferred income taxes	4	12	700,000	−6	3
Changes in fair value of contingent consideration	23	−41	−2	3	0
Loss on early extinguishment of debt	363,000	0	0	3	899,000
Accounts receivable	−2	−2	−47	−5	−9
Inventories	−7	−32	14	−79	−38
Accounts payable	−10	15	15	13	5
Income taxes	−558,000	−193,000	−4	7	−2
Accrued compensation and benefits	15	−3	14	−9	11
Other assets	−13	−14	−22	−18	−24
Other liabilities	6	−4	−10	−256,000	991,000
Net cash provided by operating activities	171	167	125	33	112
Purchases of property, plant and equipment	−20	−13	−19	−22	−15
Other	−1	0	−1	0	0
Net cash used in investing activities	−21	−13	−20	−250	−15
Payments on term loan	−100	0	−20	−93	−67
Proceeds from term loan	25	0	0	0	52
Payments on revolving line of credit	−695	−753	−760	−530	−394
Proceeds from revolving line of credit	695	751	692	460	327
Payments to redeem convertible notes	0	−70	0	−275	0
Payments related to contingent consideration	−34	−57	−14	−798,000	−6
Payments related to debt issuance costs	−3	−303,000	0	−22	−2
Dividends paid on common stock	−25	−25	−25	−24	−23
Other, net	170,000	3	16	8	11
Net cash used in financing activities	−136	−151	−110	225	−102
Effect of exchange rate changes on cash and cash equivalents	2	−3	470,000	−741,000	−2
Net increase (decrease) in cash and cash equivalents	16	163,000	−5	8	−7
Interest	25	33	34	26	22

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is CONMED Corp's CIK number?

CONMED Corp's SEC CIK number is 0000816956 (816956). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find CONMED Corp's SEC filings?

All of CONMED Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did CONMED Corp last report earnings?

CONMED Corp (CNMD) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000816956-26-000051). This is CONMED Corp's most recent earnings filing of record — not a forecast of its next earnings date.

What is CONMED Corp's most recent earnings 8-K?

CONMED Corp's latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0000816956-26-000051. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View CONMED Corp's latest earnings 8-K →
Look up any company's CIK number →